Streetbeat News

NGNE

Neurogene Inc.

https://www.neurogene.com

Industry

Biotechnology

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

Open

20.90

Mkt cap

224M

Volume

1.2M

High

20.99

P/E Ratio

-4.71

52-wk high

74.49

Low

17.01

Div yield

N/A

52-wk low

12.49

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Neurogene Inc. investors. They encourage investors who purchased Neurogene securities to inquire about the investigation.

Portfolio Pulse from

November 14, 2024 | 3:15 pm

Neurogene's stock experienced a significant drop of 44% following bad news, despite having been up 269% year-to-date. The decline began in after-hours trading on Monday and continued through Tuesday.

Portfolio Pulse from

November 14, 2024 | 12:15 pm

Levi & Korsinsky has initiated an investigation into Neurogene Inc. (NASDAQ:NGNE) for potential securities fraud. This follows Neurogene's recent press release on interim clinical data from its NGN-401 gene therapy trial for Rett syndrome.

Portfolio Pulse from

November 13, 2024 | 8:45 pm

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Neurogene Inc. (NASDAQ:NGNE) and encourages investors to participate in the investigation.

Portfolio Pulse from

November 13, 2024 | 4:45 pm

Pomerantz Law Firm is investigating claims on behalf of investors of Neurogene Inc. (NASDAQ:NGNE). Investors are encouraged to contact the firm for more information.

Portfolio Pulse from

November 13, 2024 | 4:15 pm

Neurogene Inc. announced positive interim efficacy data from its NGN-401 gene therapy clinical trial for Rett syndrome, showing favorable safety in the first four low-dose pediatric participants.

Portfolio Pulse from

November 11, 2024 | 9:15 pm

Neurogene Inc. (NASDAQ:NGNE) will present interim efficacy and safety data from its NGN-401 gene therapy trial for Rett syndrome at the CNS Annual Meeting. The presentation will include data from both low- and high-dose cohorts.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 11:32 am

HC Wainwright & Co. has maintained a Buy rating on Neurogene (NASDAQ:NGNE) but lowered the price target from $51 to $49.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 10:37 am

Neurogene (NASDAQ:NGNE) reported a Q2 2024 GAAP EPS of $(1.09), missing the analyst consensus estimate of $(1.06) by 2.83%.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 11:35 am

Neurogene's NGN-401 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for the treatment of Rett Syndrome. This designation is expected to expedite the development and review process of NGN-401, potentially bringing a new treatment option to market faster.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:36 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.